The Jett Foundation announced on July 15, 2026, the launch of a capital campaign to fund the construction of Jett's Place, a premier wellness and retreat center serving as a dedicated sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The fundraising campaign was anchored by two transformative $1 million donations from the Emilson Family and ITF Therapeutics.
Located on a 10-acre campus in Norwell, Massachusetts, Jett's Place will serve as the foundation's national headquarters and will feature barrier-free accessibility, specialized wellness care, adaptive nature and recreation, and educational programs designed with input from Duchenne families. The campaign sets a $10.7 million goal and has already raised over $5 million during its quiet phase, as the foundation invites broader community support to bring the project to life.
Duchenne muscular dystrophy is a progressive neuromuscular disorder diagnosed during childhood that causes loss of motor, pulmonary, and cardiac function, and premature death. It affects every 1 in 5,000 live male births and some females, with no cure currently available. Children with Duchenne typically lose the ability to walk around age 12 and succumb to the disease in their early to mid-twenties.
Since 2001, the Jett Foundation, headquartered in Norwell, Mass., has worked to empower people and families impacted by Duchenne through transformative programming, educational opportunities, and ongoing support for every stage of the journey. The foundation is a registered 501(c)(3) charity; more information is available at www.jettfoundation.org.
ITF Therapeutics, established in January 2024 as the U.S. affiliate of Italfarmaco Group, develops and commercializes treatments for rare diseases. The company combines end-to-end commercial execution with close listening to advocates, researchers, clinicians, and families. For more information, visit www.itftherapeutics.com.
